Mullins, C Daniel <br/><br/>
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   
 - 18-24 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1111/j.1524-4733.2009.00604.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cost Sharing<br/>Cost-Benefit Analysis--methods<br/>Drug Costs<br/>Drug Industry--economics<br/>Economics, Pharmaceutical--standards<br/>Guidelines as Topic<br/>Humans<br/>Insurance Coverage--economics<br/>Medicaid--economics<br/>Medicare--economics<br/>Outcome Assessment, Health Care--methods<br/>Prescription Fees--standards<br/>United States